Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IB/II, Randomized, Open-Label, Multicenter Study Evaluating Whether the Addition of Amifostine (Ethyol®) Will Enable the Safe Increase in Dose Intensity of Idarubicin in Combination With Cytosine Arabinoside in Older Patients With Newly Diagnosed, Previously Untreated Acute Myeloid Leukemia

NCT00086099 is registered in ClinicalTrials.gov with MedImmune LLC as lead sponsor.

NCT NCT00086099
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00086099 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IB/II, Randomized, Open-Label, Multicenter Study Evaluating Whether the Addition of Amifostine (Ethyol®) Will Enable the Safe Increase in Dose Intensity of Idarubicin in Combination With Cytosine Arabinoside in Older Patients With Newly Diagnosed, Previously Untreated Acute Myeloid Leukemia
Lead sponsor
MedImmune LLC
Phase
Phase 1/2
Overall status
Completed
Start date
July 31, 2004
Completion date
February 28, 2006
Enrollment
54 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, leukemia